Narayana Hrudayalaya Ltd
Narayana Hrudayalaya Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Organic growth trajectory is established with reasonable, steady growth expected over time. Organic revenue growth is expected to sustain current growth trajectory, supported by capacity additions and new hospital launches (Page 18).
From Narayana Hrudayalaya Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Organic growth trajectory is established with reasonable, steady growth expected over time.
- Revenue growth will be supported by organic expansion and selective inorganic augmentations.
- Upcoming quarters will see uplift from new hospital capacity in Cayman and added capacity in MMRHL hospital.
- Clinics and insurance businesses are focusing on scaling within core cities, with 50 clinics targeted next year (mainly Bangalore and Kolkata).
- Expansion will focus on smaller hospitals (200-250 beds) clustered across cities to improve patient access rather than large flagship hospitals beyond one per city.
- Growth is concentrated in 2-3 key cities over 5-7 years with potential for future rollouts based on proven success.
2 more points from Narayana Hrudayalaya Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Narayana Hrudayalaya Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current Capex is a mix of debt (about 80%) and internal accruals funding, with long-term loans of 10-20 years.
- Brownfield capacity addition mainly involves existing hospitals, capitalizing work-in-progress and settling bills, with some spillover expected to next quarters.
- Greenfield projects involve hospital construction, with typical timelines of 2-2.5 years for construction and 6-9 months for licensing/fitment, totaling around 3 years to operational startup.
- Capex focus shifted from Health City expansion (extra tower) to multiple city-wide projects like HSR, Central Bangalore, and South Bangalore.
- Expansion includes adding beds in Howrah, Barasat, and other regions, but no aggressive addition unless there is a business case.
- IRR target for brownfield projects is above 15%.
2 more points from Narayana Hrudayalaya Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Narayana Hrudayalaya Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Narayana Hrudayalaya Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.6K Cr, net profit ₹224 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Narayana Hrudayalaya Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
Arthneeti Pro · Annual
Narayana Hrudayalaya Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Narayana Hrudayalaya Ltd Q3 FY25 results?
Organic growth trajectory is established with reasonable, steady growth expected over time. Organic revenue growth is expected to sustain current growth trajectory, supported by capacity additions and new hospital launches (Page 18).
What is Narayana Hrudayalaya Ltd share price analysis?
Narayana Hrudayalaya Ltd currently shows a neutral. The stock trades at a P/E of 45.1 with a market cap of ₹38,892 Cr. Investors should review the full earnings analysis for detailed insights.
Is Narayana Hrudayalaya Ltd planning capital expenditure?
Current Capex is a mix of debt (about 80%) and internal accruals funding, with long-term loans of 10-20 years.
Keep Narayana Hrudayalaya Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.